Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
On December 20, 2021, Coherus announced the FDA approval of Yusimry (adalimumab-aqvh), a biosimilar to AbbVie’s Humira® (adalimumab).
Download PDF
Return to publications
